Page 21 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RedHill Announces FDA sNDA Approval for Talicia®

/PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the U.S. Food and Drug.

United statesUnited kingdomRedhill biopharmaColinw howdenJune almenoffAdi frishNational cancer instituteWorld health organizationCompany expanded access programCompany annual report on formCorporate business developmentEnd results programAdverse reactions to redhill biopharma incRedhill biopharma ltdUniversity of tennessee college medicineDrug administration

Pharming N : Halfjaarlijkse financiële verslaggeving -Today at 03:05 pm

Pharming Group reports second quarter and first half 2023 financial results RUCONEST® business performed strongly in 2Q 2023;.

Noord hollandDrug submission to health canadaEuropean commission decision reliance procedurePatient programTherapeutic goods administrationPharming groupnvDevices agencyEuropean medicines agencyRegulatory agencyDrug administrationExpert groupJapan pharmaceuticalsCommittee for human medicinal productsIsraeli ministry of healthAccess programPharming group

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesAdi frishRedhill biopharmaCorporate business developmentNational institute of allergyCompany expanded access programProduct development pipelineNuclear countermeasures programRedhill biopharma ltdCompany annual report on formPrnewswire redhill biopharma ltdNational institutes of healthTrademark officeEuropean patent officeExchange commission

Delcath Systems, Inc Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™

/PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the.

United statesUnited kingdomBen shamsianGerard michelPrnewswire delcath systems incAccess programVenture opportunities fundDelcath systems incDrug administrationExchange commissionPublic equityHepatic delivery systemAvenue venture opportunities fundChief executiveExpanded access programPercutaneous hepatic perfusion

Delcath Systems (DCTH) Announces Additional $35M Funding Tied to the FDA Approval of HEPZATO KIT

Delcath Systems (DCTH) Announces Additional $35M Funding Tied to the FDA Approval of HEPZATO KIT
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Gerard michelDrug administrationDelcath systems incVenture opportunities fundAccess programDelcath systemsPublic equityHepatic delivery systemAvenue venture opportunities fundChief executiveExpanded access program